Stock Events

Stock Events

Ensysce Biosciences 

$0.4010
36
+$0.00+0.5% 14:09 Today

Statistics

Day High
0.4119
Day Low
0.4
52W High
2.75
52W Low
0.23
Volume
163,558
Avg. Volume
14,661,007
Mkt Cap
7.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-3.02
-2.07
-1.13
-0.19
Expected EPS
-0.19
Actual EPS
N/A

Financials

-200.83%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
5.07MRevenue
-10.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENSC. It's not an investment recommendation.
NVIDIA
9
NVDA
Alphabet
8
GOOGL
Microsoft
7
MSFT
Legal & General Group
7
LGEN.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap8.11B
Alkermes plc focuses on central nervous system (CNS) diseases, including treatments for addiction, which competes with Ensysce's pain management and overdose protection technologies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap43.51B
Teva Pharmaceutical Industries Limited offers generic and specialty medicines, including pain management solutions that directly compete with Ensysce's product offerings.
Collegium Pharmaceutical
COLL
Mkt Cap840.39M
Collegium Pharmaceutical, Inc. specializes in pain management, offering products that could be alternatives to Ensysce's abuse-deterrent formulations.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops medications for pain management, competing in the same market as Ensysce.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie Inc. has a strong portfolio in CNS and pain management, including therapies that could compete with Ensysce's products.
Novartis
NVS
Mkt Cap301.95B
Novartis AG offers a wide range of healthcare solutions, including pain management drugs that compete with Ensysce's pipeline.
Pacira BioSciences
PCRX
Mkt Cap983.39M
Pacira BioSciences, Inc. specializes in non-opioid pain management solutions, offering alternatives to Ensysce's opioid-based treatments.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.67B
Supernus Pharmaceuticals, Inc. focuses on CNS diseases, including treatments for conditions that may require pain management solutions competing with Ensysce.

About

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Show more...
CEO
D. Lynn Kirkpatrick
Employees
10
Country
United States
ISIN
US2936025046

Listings

XNAS
US
ENSC
BOATS
BOATS
ENSC.BOATS

0 Comments

Share your thoughts

FAQ

What is Ensysce Biosciences stock price today?▼
The current price of ENSC is $0.40 USD — it has increased by +0.5% in the past 24 hours. Watch Ensysce Biosciences stock price performance more closely on the chart.
What is Ensysce Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ensysce Biosciences stocks are traded under the ticker ENSC.
Is Ensysce Biosciences stock price growing?▼
ENSC stock has risen by +7.96% compared to the previous week, the month change is a +60.56% rise, over the last year Ensysce Biosciences has showed a -80.81% decrease.
What is Ensysce Biosciences market cap?▼
Today Ensysce Biosciences has the market capitalization of 7.8M
When is the next Ensysce Biosciences earnings date?▼
Ensysce Biosciences is going to release the next earnings report on November 16, 2026.
What is Ensysce Biosciences revenue for the last year?▼
Ensysce Biosciences revenue for the last year amounts to 5.07M USD.
What is Ensysce Biosciences net income for the last year?▼
ENSC net income for the last year is -10.18M USD.
How many employees does Ensysce Biosciences have?▼
As of August 28, 2026, the company has 10 employees.
In which sector is Ensysce Biosciences located?▼
Ensysce Biosciences operates in the Health & Wellness sector.
When did Ensysce Biosciences complete a stock split?▼
The last stock split for Ensysce Biosciences was on December 06, 2024 with a ratio of 1:15.
Where is Ensysce Biosciences headquartered?▼
Ensysce Biosciences is headquartered in LA JOLLA, United States.